The University of Texas Southwestern Medical Center (UTSW) has a history of leadership, translational research, and accrual to cooperative group trials. The PI of this grant is Dr. Joan Schiller, chief of the Division of Heme/Oncology and Deputy Director of the Simmons Cancer Center (SCC), former Chair of ECOG's Thoracic Committee and currently PI of UTSW's main institution ECOG grant. Co-investigators include Dr. Hak Choy, Chair of UTSW's Department of Radiation Oncology, Vice Chair for Disease Sites in RTOG, and former Chair of RTOG's Thoracic Committee;Dr. David Miller, member of the GOG Board of Directors and Chair of the Uterine Corpus Committee;Dr. Marilyn Leitch, member of the Executive Committee of ACOSOG, and Dr. Phil Evans, immediate past president of the American Cancer Society, who was one of the founding members of the ACRIN Breast committee, and served as the principal investigator at UTSW for ACRIN sponsored trials. In 2012, UTSW enrolled 105 patients on adult co-operative group trials. Since 2006, UTSW faculty have investigated or co-investigated 96 co-operative group publications and 85 abstracts, and have chaired, co-chaired, or served as cooperative committee chair on 34 cooperative group trials. UTSW is also a site for the NCI Centers Quantitative imaging Excellence. UTSW is the only academic medical center and medical school in the Dallas/Ft. Worth (DFW) Metroplex, the fourth largest metropolitan area in the country, and is the only NCI designated Cancer Center in north Texas. UTSW also has a strong clinical and transitional research program and drug discovery program;a SPORE in lung cancer;an Advanced Imaging Research Center;and has access to a diverse ethnic and racial population. In the DFW Metroplex, roughly 10.3% of the populations with a cancer diagnosis are Hispanic, and 14.1% are African American;in 2012, 29.6% of SCC patients going on co-operative group clinical studies were of Hispanic ethnicity, and 13.6% were of African American ancestry.
The specific aims of the UTSW UIO are to contribute to and promote: (1) The NCTN by enrolling patients with diverse ethnic and racial background on therapeutic and non-therapeutic trials;(2) The scientific direction of the NCTN by bringing the basic, translational, and imaging research conducted at UTSW into hypothesis driven clinical trials. (3) Multidisciplinary efforts and collaboration across multiple disciplinesand multiple cooperative groups;(4) Service in leadership roles by chairing and co-chairing clinical trials and committees, and by participating in NCI activities and initiatives;and (5) The career development of junior faculty.

Public Health Relevance

The University of Texas Southwestern Medical Center brings to the NCTN a history of leadership in multiple cooperative groups and excellent accrual to cooperative group trials, Including ethnic and racial minorities. Other strengths include our innovative basic research and drug discovery which can be translated to clinic research, an Advanced imaging Center, and our unique position as the only NCI designated Cancer Center and academic medical center in the fourth largest metropolitan area in the country.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel ()
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Gerber, David E; Urbanic, James J; Langer, Corey et al. (2016) Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer :
Gerber, David E; Spigel, David R; Giorgadze, David et al. (2016) Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer 17:169-76
Levin, Pavel A; Brekken, Rolf A; Byers, Lauren Averett et al. (2016) Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. J Thorac Oncol 11:1357-62
Al-Hallaq, Hania A; Chmura, Steven; Salama, Joseph K et al. (2016) Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol 6:e291-e298
Dietrich, Martin F; Collins Jr, Robert H; Gerber, David E (2016) Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer. JAMA Oncol 2:132-3
Khan, Saad A; Pruitt, Sandi L; Xuan, Lei et al. (2016) Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. JAMA Oncol 2:1507-1508
Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8
Laccetti, Andrew L; Chen, Beibei; Cai, Jennifer et al. (2016) Increase in Cancer Center Staff Effort Related to Electronic Patient Portal Use. J Oncol Pract :
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Moore, Kathleen N; Java, James J; Slaughter, Katrina N et al. (2016) Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol 143:294-301

Showing the most recent 10 out of 35 publications